Document is current
Any future updates will be listed below
-
Authors
Niedbalski, Peter J. https://orcid.org/0000-0002-0528-2508
Castro, Mario
- License Information
-
More Information
Article History
Received: 6 May 2024
Revised: 6 May 2024
Accepted: 10 May 2024
First Online: 31 May 2024
Compliance with ethical standards
:
: The scientific guarantor of this publication is Peter Niedbalski.
: The authors of this manuscript declare relationships with the following companies: Peter J. Niedbalski receives research support from the American Heart Association, the National Scleroderma Foundation, and NIH. He is a consultant for Polarean Imaging, Plc, a company that develops hyperpolarized <sup>129</sup>Xe technology. Mario Castro receives research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance Biopharma. He is a consultant for Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, Sanofi-Aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals. He receives speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi. He receives royalties from Aer Therapeutics.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required.
: Institutional Review Board approval was not required.
: Not applicable
:
